This 2011 study from the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) compared radical prostatectomy to watchful waiting in 695 men with early-stage prostate cancer over a median follow-up of 12.8 years. The findings indicated that radical prostatectomy significantly reduced prostate cancer-specific mortality (14.6% vs. 20.7% at 15 years;
This 2023 expert commentary discusses the 15-year follow-up results of the ProtecT trial, which compared active monitoring, radical prostatectomy, and radiotherapy in men with localized prostate cancer. The trial found no statistically significant difference in prostate cancer-specific mortality among the three treatment modalities, with overall mortality remaining low across the
This 2020 retrospective study evaluated 875 patients post-radical prostatectomy, analyzing the effect of statin use on biochemical recurrence (BCR). Statin use at the time of surgery was reported in 45.7% of patients. Over a median follow-up of 51.2 months, statin users had a significantly reduced risk of BCR (HR 0.599,
This 2017 review examines the comparative effectiveness of various treatment modalities for clinically localized prostate cancer, focusing on oncologic control. It evaluates radical prostatectomy, radiation therapy, and observation strategies, highlighting the trade-offs between treatment benefits and potential harms. The review also discusses emerging therapies such as cryotherapy and high-intensity focused
This 2001 Phase II randomized trial evaluated the effects of lycopene supplementation (15 mg twice daily for 3 weeks) in 26 men with localized prostate cancer prior to radical prostatectomy. Compared to the control group, lycopene supplementation was associated with a higher proportion of smaller tumors (
This randomized controlled trial assessed the long-term outcomes of radical prostatectomy versus observation in men with localized prostate cancer. Over a median follow-up of 12.7 years, there was no significant difference between the two groups in all-cause mortality or prostate cancer-specific mortality. Surgery was associated with a higher frequency of
This large-scale longitudinal study assessed the functional and quality of life outcomes in 2,565 men aged 50–69 with localized prostate cancer, randomized to active monitoring (AM), radical prostatectomy (RP), external-beam radiotherapy (EBRT) with androgen deprivation therapy (ADT), or low-dose-rate brachytherapy (BT). Over six years, AM was associated with gradual declines
This 2013 cohort study analyzed 1,315 men who underwent radical prostatectomy between 1995 and 2009 to assess the impact of 5α-reductase inhibitors (5-ARIs) and alpha-blockers on tumor grade and biochemical recurrence. Long-term use (≥4 years) of 5-ARIs (finasteride or dutasteride) was associated with a higher proportion of high-grade tumors (Gleason
This 2019 review by Morgentaler and Caliber examines the evolving perspective on testosterone therapy (TTh) in men with prostate cancer (PCa). Historically contraindicated, TTh is now considered a viable option for certain patients. The review discusses the “saturation model,” which suggests that prostate tissue’s response to androgens plateaus beyond a
This randomized controlled trial compared radical prostatectomy (RP) with watchful waiting (WW) in 695 men with early prostate cancer over a median follow-up of 12 years, assessing symptom burden, androgen deprivation therapy (ADT) use, and quality of life (QoL). RP was associated with lower prostate cancer-specific mortality but higher rates
